Introduction
============

It has recently been reported that metabolically driven low-grade and chronic inflammation is observed in various types of metabolic disorders, including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease.[@b1-cmc-suppl.3-2014-023],[@b2-cmc-suppl.3-2014-023] The atypical inflammation emerging from metabolic tissues is referred to as metaflammation. Metaflammation is triggered by a surplus of nutrients and metabolites that engage a group of molecules with signaling pathways involved in canonical inflammation. Such signal pathways are mediated by c-Jun N-terminal kinase (JNK), inhibitor of nuclear kappa B kinase (IKK), double-stranded RNA-dependent protein kinase (PKR), and others,[@b1-cmc-suppl.3-2014-023],[@b2-cmc-suppl.3-2014-023] and are responsible for the inhibition of insulin signaling and a vicious cycle of further production of inflammatory mediators through transcriptional regulation by activating protein-1 (AP-1) and nuclear factor-kappa B (NF-κB).[@b3-cmc-suppl.3-2014-023]--[@b5-cmc-suppl.3-2014-023]

In this article, we focus on fatty acid-binding proteins (FABPs) derived from metabolically active cells, especially FABP4, and discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker in the context of metabolic and cardiovascular diseases.

Fatty Acid-Binding Proteins
===========================

FABPs are a family of 14--15-kDa proteins, known as intracellular lipid chaperones, that regulate lipid trafficking and responses in cells.[@b6-cmc-suppl.3-2014-023],[@b7-cmc-suppl.3-2014-023] FABPs can reversibly bind to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids (FAs), eicosanoids, and other lipids, with high affinity and broad selectivity.[@b8-cmc-suppl.3-2014-023],[@b9-cmc-suppl.3-2014-023] FABPs are found in all species, from *Caenorhabditis elegans* and *Drosophila melanogaster* to rodents and humans, demonstrating strong evolutionary conservation.[@b10-cmc-suppl.3-2014-023]--[@b12-cmc-suppl.3-2014-023] Since the first report of FABPs in 1972,[@b13-cmc-suppl.3-2014-023] at least nine different isoforms have been identified in mammals to date. Different isoforms of the FABP family are uniquely expressed in tissues involved in active lipid metabolism. In general, the amount of FABP in cells is proportional to the rates of FA metabolism.[@b14-cmc-suppl.3-2014-023] The family consists of liver (L-FABP/FABP1), intestinal (I-FABP/FABP2), heart (H-FABP/FABP3), adipocyte (A-FABP/FABP4/aP2), epidermal (E-FABP/FABP5/mal1), ileal (Il-FABP/FABP6), brain (B-FABP/FABP7), myelin (M-FABP/FABP8), and testis (T-FABP/FABP9) isoforms.

FABPs exhibit about 15--70% sequence identity between different isoforms.[@b11-cmc-suppl.3-2014-023] However, FABPs share almost similar three-dimensional structures, showing two orthogonal five-stranded β-sheets by a 10-stranded anti-parallel β-barrel structure.[@b6-cmc-suppl.3-2014-023],[@b11-cmc-suppl.3-2014-023] The FA-binding pocket is located inside the β-barrel, and usually, one long-chain FA can be bound to the interior cavity of FABPs except for FABP1. There are differences between the different isoforms in binding affinity and ligand selectivity because of structural differences.[@b11-cmc-suppl.3-2014-023] In general, hydrophobic ligand has a tight binding affinity for FABPs, except for unsaturated FAs.

FABPs have been proposed to actively facilitate the transport of FAs to specific organelles in the cell for lipid oxidation in the mitochondrion or peroxisome; lipid-mediated transcriptional regulation in the nucleus; signaling, trafficking, and membrane synthesis in the endoplasmic reticulum (ER); and regulation of enzyme activity and storage as lipid droplets in the cytoplasm.[@b6-cmc-suppl.3-2014-023] FABPs are also involved in the conversion of FAs to eicosanoids and the stabilization of leukotriene.[@b15-cmc-suppl.3-2014-023],[@b16-cmc-suppl.3-2014-023]

FABPs in Adipocytes: FABP4 and FABP5
====================================

FABP4, also known as adipocyte FABP (A-FABP), was first detected in adipose tissue and mature adipocytes.[@b17-cmc-suppl.3-2014-023],[@b18-cmc-suppl.3-2014-023] This protein has also been termed adipocyte P2 (aP2) since there is high sequence similarity (67%) with the myelin P2 protein (M-FABP/FABP8).[@b18-cmc-suppl.3-2014-023] FABP4 is highly expressed in adipocytes and consists of about 1% of all soluble proteins in adipose tissue.[@b19-cmc-suppl.3-2014-023] Expression of FABP4 is highly induced during adipocyte differentiation and transcriptionally controlled by peroxisome proliferator-activated receptor (PPAR) γ agonists, FAs, dexamethasone, and insulin.[@b20-cmc-suppl.3-2014-023]--[@b24-cmc-suppl.3-2014-023]

FABP4-deficient mice showed an increase in body weight but reduced insulin resistance in both high-fat diet-induced and genetic obesity mouse models, but the effect of FABP4 on insulin sensitivity was not observed in lean mice ([Fig. 1](#f1-cmc-suppl.3-2014-023){ref-type="fig"}).[@b25-cmc-suppl.3-2014-023],[@b26-cmc-suppl.3-2014-023] It has been postulated that FABP4 activates hormone-sensitive lipase (HSL) in adipocytes, regulating lipolysis.[@b27-cmc-suppl.3-2014-023],[@b28-cmc-suppl.3-2014-023] In fact, FABP4-deficient adipocytes exhibited reduced efficiency of lipolysis.[@b29-cmc-suppl.3-2014-023],[@b30-cmc-suppl.3-2014-023] Knockdown of *Fabp4* gene by RNA interference in dietary obese mice increased body weight and fat mass without significant changes in glucose and lipid homeostasis.[@b31-cmc-suppl.3-2014-023] The phenotypic feature of *Fabp4*-knockdown mice is similar to the phenotype of FABP4 heterozygous knockout mice on a high-fat diet,[@b25-cmc-suppl.3-2014-023] indicating that remaining FABP4 protein sustains some elements of FABP4 function in control mice. The loss of FABP4 in adipocytes is compensated by FABP5, an FABP known as E-FABP or mal1.[@b25-cmc-suppl.3-2014-023]

FABP5 is most abundantly present in epidermal cells of the skin but is also expressed in several other cells and tissues including adipocytes.[@b6-cmc-suppl.3-2014-023] The amount of FABP5 is about 100-fold lesser than that of FABP4 in adipocytes.[@b32-cmc-suppl.3-2014-023] FABP4 and FABP5 have 52% amino acid similarity and bind to several FAs with similar affinity and selectivity.[@b10-cmc-suppl.3-2014-023]

In transgenic mice in which FABP5 was overexpressed in adipose tissue, basal lipolysis and hormone-stimulated lipolysis were enhanced, and insulin sensitivity was reduced in mice on a high-fat diet.[@b33-cmc-suppl.3-2014-023],[@b34-cmc-suppl.3-2014-023] FABP5 deficiency mildly increased systemic insulin sensitivity in dietary and genetic obesity mouse models.[@b33-cmc-suppl.3-2014-023] FABP5-deficient adipocytes demonstrated an increased capacity for insulin-stimulated glucose transport. Except for increased FABP3 (H-FABP) in the liver,[@b35-cmc-suppl.3-2014-023] there was no compensatory increase in the expression of FABPs in tissues of FABP5-deficient mice.[@b33-cmc-suppl.3-2014-023]

FABPs in Macrophages: FABP4 and FABP5
=====================================

Both FABP4 and FABP5 are also expressed in macrophages and dendritic cells,[@b36-cmc-suppl.3-2014-023],[@b37-cmc-suppl.3-2014-023] though the amount of FABP4 in adipocytes is about 10,000-fold higher than that in macrophages.[@b38-cmc-suppl.3-2014-023] Under physiological conditions, the stoichiometry of FABP4 and FABP5 appears to be nearly equal in macrophages.[@b36-cmc-suppl.3-2014-023] Unlike in adipocytes, FABP5 did not appear to be significantly upregulated in FABP4-deficient macrophages.[@b36-cmc-suppl.3-2014-023] The mechanism underlying compensatory changes in FABPs is unknown.

Expression of FABP4 is induced during differentiation from monocytes to macrophages and by treatment with lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate, PPARγ agonists, oxidized low-density lipoprotein, and advanced glycation end products.[@b36-cmc-suppl.3-2014-023],[@b39-cmc-suppl.3-2014-023]--[@b43-cmc-suppl.3-2014-023] Conversely, atorvastatin, a cholesterol-lowering drug, has been shown to reduce FABP4 expression in macrophages.[@b44-cmc-suppl.3-2014-023] Metformin, an antidiabetic drug, has also been reported to inhibit forkhead box protein O1 (FOXO1)-mediated transcription of FABP4 and reduce lipid accumulation in macrophages.[@b45-cmc-suppl.3-2014-023]

In macrophages, FABP4 increases accumulation of cholesterol ester and foam cell formation via inhibition of the PPARγ-liver X receptor α (LXRα)-ATP-binding cassette A1 (ABCA1) pathway and induces inflammatory responses through activation of the IKK-NF-κB and JNK-AP-1 pathways.[@b46-cmc-suppl.3-2014-023],[@b47-cmc-suppl.3-2014-023] Ablation of FABP4 protected against atherosclerosis in apolipoprotein E (ApoE)-deficient mice with or without high-cholesterol western-style diets ([Fig. 1](#f1-cmc-suppl.3-2014-023){ref-type="fig"}).[@b36-cmc-suppl.3-2014-023],[@b48-cmc-suppl.3-2014-023] Bone marrow transplantation studies demonstrated that actions in macrophages are predominant for the protective effect of FABP4 deficiency on atherosclerosis rather than actions in adipocytes.[@b36-cmc-suppl.3-2014-023] FABP4 in dendritic cells has been shown to regulate the IKK-NF-κB pathway and T-cell priming,[@b37-cmc-suppl.3-2014-023] which might contribute to the development of atherosclerosis since both dendritic cells and T-cells are involved in the pathogenesis of atherosclerosis.[@b49-cmc-suppl.3-2014-023] As evidence of atherosclerosis in humans, expression of FABP4 in macrophages has been shown to be increased in unstable carotid plaques of human endarterectomy samples.[@b50-cmc-suppl.3-2014-023]

Expression of FABP5 in macrophages is increased by treatment with toll-like receptor (TLR) agonists: LPS, a TLR4 agonist, and zymosan, a fungal product that activates TLR2.[@b51-cmc-suppl.3-2014-023] In addition to FABP4, FABP5 may also play a role in atherosclerosis via TLRs and/or other mechanisms. Ablation of FABP5 suppressed atherosclerosis in LDL receptor-deficient mice on a western-style hypercholesterolemic diet, and the anti-atherosclerotic effect of FABP5 deletion was associated with reduction of the expression of inflammatory genes, interleukin 6 and cyclooxygenase-2, and suppression of macrophage recruitment in atherosclerotic lesions because of decreased expression of CC chemokine receptor 2.[@b52-cmc-suppl.3-2014-023]

Combined Deficiency of FABP4 and FABP5
======================================

As described above, both FABP4 and FABP5 in adipocytes and macrophages play important roles in the development of insulin resistance and atherosclerosis ([Fig. 1](#f1-cmc-suppl.3-2014-023){ref-type="fig"}).[@b25-cmc-suppl.3-2014-023],[@b26-cmc-suppl.3-2014-023],[@b33-cmc-suppl.3-2014-023],[@b36-cmc-suppl.3-2014-023],[@b48-cmc-suppl.3-2014-023],[@b52-cmc-suppl.3-2014-023] Mice with combined deficiency of FABP4 and FABP5 (*Fabp4*^−/−^*Fabp5*^−/−^) on dietary and genetic obesity models exhibited improvement in insulin resistance and protection against type 2 diabetes and fatty liver disease more than did FABP4-or FABP5-deficient mice.[@b53-cmc-suppl.3-2014-023],[@b54-cmc-suppl.3-2014-023] Macrophage infiltration and accumulation in adipose tissue has been suggested to be an important feature of obesity-triggered metaflammation.[@b55-cmc-suppl.3-2014-023],[@b56-cmc-suppl.3-2014-023] Although the effect of FABP4 or FABP5 on atherosclerosis was mainly due to their actions in macrophages,[@b36-cmc-suppl.3-2014-023],[@b52-cmc-suppl.3-2014-023] bone marrow transplantation and cell-based co-culture experiments with adipocytes and macrophages using wild-type and *Fabp4*^−/−^*Fabp5*^−/−^ mice showed that FABP actions in adipocytes and those in macrophages have distinct roles in regulation of insulin sensitivity through metabolic and inflammatory responses.[@b57-cmc-suppl.3-2014-023] Furthermore, *Fabp4*^−/−^*Fabp5*^−/−^ mice intercrossed into an ApoE-deficient atherosclerosis model showed dramatically suppressed development of atherosclerosis compared to that in FABP4-deficient or wild-type mice on the same background.[@b58-cmc-suppl.3-2014-023] Interestingly, *Fabp4*^−/−^*Fabp5*^−/−^*Apoe*^−/−^ mice on a hypercholesterolemic diet also had a significantly higher survival rate than that of *Apoe*^−/−^ mice, probably due to better plaque stability and metabolic health.[@b58-cmc-suppl.3-2014-023]

Lipidomic analyses using samples from different tissues, including adipose tissue, skeletal muscle, liver, and blood in *Fabp4*^−/−^*Fabp5*^−/−^ and wild-type mice, showed significantly increased de novo lipogenesis by induction of stearoyl-CoA desaturase-1 (SCD-1) and FA synthase in adipose tissue.[@b59-cmc-suppl.3-2014-023] As a result, palmitoleate (C16:1n7), an unsaturated free FA, was identified as an adipose tissue-derived lipid hormone, referred to as lipokine, that decreases fatty liver and increases glucose uptake in skeletal muscle.[@b59-cmc-suppl.3-2014-023] Deletion of FABP4 in macrophages also increased de novo lipogenesis pathways through LXRα-mediated SCD-1 activation, resulting in production of palmitoleate and resistance to ER stress.[@b60-cmc-suppl.3-2014-023] Conversely, unsaturated FAs, including palmitoleate, modulated histone deacetylation, resulting in decreased basal and LPS-induced expression of FABP4 in macrophages.[@b61-cmc-suppl.3-2014-023]

A role of a lipokine in human pathophysiology has been suggested by recent clinical studies. In a study in which 100 Caucasian subjects were recruited, palmitoleate level was positively correlated with insulin sensitivity assessed by euglycemic-hyperinsulinemic clamp studies, independent of age, gender, and adiposity.[@b62-cmc-suppl.3-2014-023] Another study in which 3630 subjects in the US were enrolled showed that high level of *cis* isomer palmitoleate, which is primarily produced by the liver in humans, was associated with adiposity and consumption of alcohol and carbohydrate.[@b63-cmc-suppl.3-2014-023] Interestingly, it has recently been reported that the level of *trans* isomer of palmitoleate, an exogenous source of C16:1n7, is associated with lower insulin resistance, lower incidence of diabetes, and higher HDL-cholesterol level, suggesting a potential strategy for intervention by metabolic benefits of dairy product consumption in human diseases.[@b64-cmc-suppl.3-2014-023]

Potential Functional Domains of FABP4
=====================================

A nuclear localization signal (NLS) and a nuclear export signal (NES) have been reported in potential functional domains of FABP4.[@b6-cmc-suppl.3-2014-023],[@b65-cmc-suppl.3-2014-023],[@b66-cmc-suppl.3-2014-023] The primary sequence of FABP4 does not reveal a typical NLS or NES. However, the signals could be found in the three-dimensional structure of FABP4 and were mapped to three basic residues (K21, R30, and K31) for NLS in the helix--loop--helix region and three nonadjacent leucine residues (L66, L86, and L91) for NES.[@b65-cmc-suppl.3-2014-023] The NLS in FABP4 is activated by closure of the portal loop and perturbation of a swinging doorway comprised F57.[@b66-cmc-suppl.3-2014-023] Non-activating ligands, such as oleate and stearate, protrude from the portal and prevent its closure, leading to the masking of the NLS, while activating ligands, such as linoleic acid, troglitazone, and anilinonaphthalene sulfonate, expose the NLS.[@b66-cmc-suppl.3-2014-023]

As a small intracellular protein, FABP4 may access the nucleus and target FAs to transcription factors, such as members of the PPAR family, in the nuclear lumen. It has been reported that FABP4 expression itself is controlled by PPARγ.[@b67-cmc-suppl.3-2014-023] A recent study has indicated that continuous shuttling between the nucleus and cytoplasm is involved in transcriptional activation of PPARγ by FABP4.[@b65-cmc-suppl.3-2014-023] However, it has also been shown that FABP4 has inhibitory action of PPARγ in macrophages.[@b46-cmc-suppl.3-2014-023]

Another domain of FABP4 includes an HSL binding site.[@b6-cmc-suppl.3-2014-023],[@b28-cmc-suppl.3-2014-023] A direct protein--protein interaction between FABP4 and HSL activity in adipocytes has been reported to regulate lipolysis.[@b27-cmc-suppl.3-2014-023],[@b29-cmc-suppl.3-2014-023],[@b30-cmc-suppl.3-2014-023] Adipocytes in FABP4-deficient mice have reduced lipolysis *in vitro* and *in vivo*. Interestingly, during experimentally induced lipolysis, FABP4-deficient mice showed reduction in insulin secretion.[@b29-cmc-suppl.3-2014-023]

FABP4 has been reported to decrease Janus kinase 2 (JAK2) signaling via protein--protein interaction, indicating a novel role of FABP4 as a FA sensor affecting metabolism in the cell.[@b68-cmc-suppl.3-2014-023] Phosphatase and tensin homolog on chromosome 10 (PTEN), which negatively regulates the phosphoinositide 3-kinase pathway, has also been reported to interact with FABP4, possibly regulating adipocyte differentiation and lipid metabolism.[@b69-cmc-suppl.3-2014-023] Interestingly, PTEN-deficient keratinocytes increased expression of FABP4, suggesting that PTEN transcriptionally regulates FABP4 expression.[@b70-cmc-suppl.3-2014-023]

Secretion of FABP4 as an Adipokine
==================================

FABP4 lacks an N-terminal secretory signal sequence,[@b6-cmc-suppl.3-2014-023] which is necessary for the classical secretory pathway, ie, ER--Golgi-dependent pathway. However, proteins can also be actively secreted from eukaryotic cells via ER--Golgi-independent pathways.[@b71-cmc-suppl.3-2014-023] Previous studies demonstrated that FABP4 secretion was not modulated by treatment with brefeldin A and monensin, inhibitors of protein secretion by blocking vesicular traffic at the ER and the Golgi apparatus, indicating a non-classical secretion mechanism for FABP4.[@b72-cmc-suppl.3-2014-023],[@b73-cmc-suppl.3-2014-023]

In adipocytes, there are two distinct signal pathways of activation of lipolysis by phosphorylation of HSL: β-adrenergic receptor-mediated adenyl cyclase (AC)-protein kinase A (PKA) and natriuretic peptide receptor-A (NPR-A)-mediated guanylyl cyclase (GC)-protein kinase G (PKG) pathways.[@b74-cmc-suppl.3-2014-023],[@b75-cmc-suppl.3-2014-023] We recently showed that FABP4 is secreted from adipocytes in association with lipolysis through both AC-PKA and GC-PKG pathways ([Fig. 2](#f2-cmc-suppl.3-2014-023){ref-type="fig"}).[@b76-cmc-suppl.3-2014-023] Since it has been reported that lipolysis is mediated in part through the interaction of FABP4 with HSL in adipocytes,[@b27-cmc-suppl.3-2014-023],[@b29-cmc-suppl.3-2014-023],[@b30-cmc-suppl.3-2014-023] there is a dual regulatory mechanism of FABP4 secretion in adipocytes. FABP4 may also be a carrier protein for transport of FAs generated by lipolysis from lipid droplets to extracellular and/or intracellular utilization. In humans, plasma FABP4 level significantly declined after an oral glucose tolerance test or after eating a high-fat meal, while the insulin level increased.[@b76-cmc-suppl.3-2014-023] Suppression of FABP4 secretion by insulin-induced anti-lipolytic signaling may be involved in this decline in FABP4 level.

FABP4 secretion from human adipocytes has also been shown to be increased by ionomycin, an ionophore that raises intracellular Ca^2+^ levels, indicating contribution of a calcium-dependent secretory mechanism.[@b77-cmc-suppl.3-2014-023] In addition, FABP4 is secreted partially by microvesicles derived from adipocytes (an established mechanism for unconventional secretion from adipocytes[@b71-cmc-suppl.3-2014-023]), and both microvesicle-free-mediated and microvesicle-secreted FABP4 are downregulated by insulin and upregulated by ionomycin.[@b73-cmc-suppl.3-2014-023],[@b76-cmc-suppl.3-2014-023],[@b78-cmc-suppl.3-2014-023] However, the release of FABP4 via adipocyte-derived microvesicles is a small fraction and conveys a minor activity.[@b76-cmc-suppl.3-2014-023],[@b78-cmc-suppl.3-2014-023] Taken together, the findings indicate that FABP4 is actively released by unconventional mechanisms and by adipocyte-derived microvesicles from adipocytes through AC-PKA- and GC-PKG-dependent signal pathways and/or an intracellular calcium-dependent mechanism.

Proteomic analysis showed the presence of FABP4 in cell supernatants derived from differentiated THP-1 macrophages,[@b79-cmc-suppl.3-2014-023] suggesting that FABP4 is also secreted from macrophages. In bone marrow transplantation using wild-type and FABP4/5-deficient mice, bone marrow-derived cells from wild-type mice could not sustain a detectable level of plasma FABP4 in FABP4/5-deficient mice, indicating that the predominant contributors of circulating FABP4 are adipocytes rather than macrophages.[@b72-cmc-suppl.3-2014-023] The biological roles of extracellular FABP4 derived from macrophages remain unknown, but there might be local effects of macrophage-derived FABP4 on metaflammation.

Evidences supporting extracellular roles of FABP4 as an adipokine are accumulating with great importance. The secreted form of FABP4 may be biologically active, leading to a paradigm shift in the understanding of FABPs as lipid chaperones and the local networking of metabolic and inflammatory responses ([Fig. 3](#f3-cmc-suppl.3-2014-023){ref-type="fig"}). Direct effects of exogenous FABP4 have been demonstrated in multiple types of cells; FABP4 enhanced hepatic glucose production *in vivo* and *in vitro*,[@b72-cmc-suppl.3-2014-023] decreased cardiomyocyte contraction *in vitro*,[@b78-cmc-suppl.3-2014-023] inhibited expression/activation of endothelial nitric oxide synthase (eNOS) in vascular endothelial cells,[@b80-cmc-suppl.3-2014-023] and increased proliferation/migration of vascular smooth muscle cells[@b81-cmc-suppl.3-2014-023] and glucose-stimulated insulin secretion in pancreatic β cells.[@b82-cmc-suppl.3-2014-023] Future investigation should provide further insights into extracellular roles of FABP4 and how they contribute to progression of diseases.

Circulating Concentration of FABP4 as a Potent Biomarker
========================================================

Recent studies have shown the presence of FABPs in human circulation. Since FABPs lack a secretory signal sequence,[@b6-cmc-suppl.3-2014-023] the detection of FABPs in circulation is thought to be a biochemical marker of tissue injury in related cells: FABP1 (L-FABP) for liver injury,[@b83-cmc-suppl.3-2014-023],[@b84-cmc-suppl.3-2014-023] FABP2 (I-FABP) for intestinal damage,[@b83-cmc-suppl.3-2014-023],[@b85-cmc-suppl.3-2014-023] FABP3 (H-FABP) for ongoing myocardial damage in acute myocardial infarction or heart failure,[@b86-cmc-suppl.3-2014-023],[@b87-cmc-suppl.3-2014-023] and FABP7 (B-FABP) for brain injury.[@b83-cmc-suppl.3-2014-023],[@b88-cmc-suppl.3-2014-023]

On the other hand, it has been shown that FABP4 is secreted from adipocytes and may act as an adipokine as described above. FABP4 concentration was the highest among levels of FABP1--5 under a physiological condition in a general population without pharmacological treatments.[@b89-cmc-suppl.3-2014-023] FABP4 level is significantly higher in females than in males, possibly because of the larger amount of body fat in females than in males since there is an independent and strong correlation between FABP4 level and adiposity.[@b89-cmc-suppl.3-2014-023],[@b90-cmc-suppl.3-2014-023] Consistent with the results of previous studies showing that levels of several FABPs were increased in subjects with renal dysfunction,[@b84-cmc-suppl.3-2014-023],[@b91-cmc-suppl.3-2014-023],[@b92-cmc-suppl.3-2014-023] serum FABP4 level was shown to be negatively correlated with estimated glomerular filtration rate in recent studies,[@b89-cmc-suppl.3-2014-023],[@b93-cmc-suppl.3-2014-023] suggesting that FABPs are eliminated from the circulation mainly by renal clearance. We previously showed that FABP4 level in hemodialysis patients with end-stage kidney disease was about 20 times higher than that in controls with normal renal function and was decreased by 57.2% after hemodialysis.[@b94-cmc-suppl.3-2014-023]

It has been reported that increased circulating FABP4 levels are associated with obesity, insulin resistance, type 2 diabetes, hypertension, cardiac dysfunction, and atherosclerosis.[@b90-cmc-suppl.3-2014-023],[@b95-cmc-suppl.3-2014-023]--[@b99-cmc-suppl.3-2014-023] Circulating FABP4 level was significantly increased in obese subjects compared to the level in lean controls, and serum FABP4 level was positively correlated with waist circumference, blood pressure, and insulin resistance.[@b90-cmc-suppl.3-2014-023] High concentration of FABP4 at baseline was an independent predictor for the development of metabolic syndrome during a five-year follow-up period in a Chinese population.[@b95-cmc-suppl.3-2014-023] A 10-year prospective study also showed that high level of FABP4 at baseline independently predicted the development of type 2 diabetes.[@b96-cmc-suppl.3-2014-023] We previously demonstrated significant elevation of circulating FABP4 level in patients with essential hypertension and insulin resistance, correlation of FABP4 concentration with indices of insulin resistance, and association of elevation of FABP4 level with family history of hypertension, suggesting a role of FABP4 in genetic predispositions for the development of essential hypertension.[@b97-cmc-suppl.3-2014-023] Associations of FABP4 levels with the development of left ventricular (LV) hypertrophy and with systolic and diastolic cardiac dysfunction have also been reported.[@b100-cmc-suppl.3-2014-023]--[@b104-cmc-suppl.3-2014-023] Our recent study demonstrated that FABP4 level was associated with LV diastolic dysfunction even in an apparently healthy population with no medication.[@b98-cmc-suppl.3-2014-023] It has also been reported that serum FABP4 level is associated with atherosclerosis assessed by carotid intima-media thickness.[@b99-cmc-suppl.3-2014-023] These findings support the notion that circulating FABP4 is not only a potent biomarker but also plays an important role, as an adipokine, in the development of metabolic syndrome and cardiovascular diseases ([Fig. 3](#f3-cmc-suppl.3-2014-023){ref-type="fig"}).

A genetic variant at the FABP4 locus associated with decreased FABP4 expression in adipose tissue has been suggested to reduce the risk of cardiovascular diseases in a population study.[@b105-cmc-suppl.3-2014-023] We and others previously showed that serum FABP4 level predicts long-term cardiovascular events.[@b94-cmc-suppl.3-2014-023],[@b106-cmc-suppl.3-2014-023],[@b107-cmc-suppl.3-2014-023] Furthermore, a large-scale prospective study showed that concentration of FABP4 predicts the risk of heart failure during a median follow-up of 10.7 years.[@b108-cmc-suppl.3-2014-023] Accumulating evidences of a causative role of FABP4 in cardiovascular events, including atherosclerosis and cardiac dysfunction, indicate that FABP4 is potentially a novel target for prevention of cardiovascular diseases ([Fig. 3](#f3-cmc-suppl.3-2014-023){ref-type="fig"}). Other than cardiovascular pathologic processes, FABP4 level has been shown to be a novel prognostic factor in patients with breast cancer independent of obesity.[@b109-cmc-suppl.3-2014-023]

It has been reported that several drugs modify circulating FABP4 levels. Atorvastatin, a HMG-CoA reductase inhibitor, and several angiotensin II receptor blockers reduced FABP4 concentrations.[@b110-cmc-suppl.3-2014-023]--[@b112-cmc-suppl.3-2014-023] On the other hand, pioglitazone, an insulin-sensitizing thiazolidinedione (a PPARγ agonist), increased FABP4 levels,[@b113-cmc-suppl.3-2014-023] presumably because of direct activation of PPARγ since the *Fabp4* gene promoter includes the PPAR response element.[@b114-cmc-suppl.3-2014-023]

Of note, similar to FABP4, circulating FABP5 has been reported to be detected at levels of about 1/10th or less of FABP4 concentrations, and FABP5 levels were associated with components of metabolic syndrome, although the correlation was not as strong as that of FABP4.[@b89-cmc-suppl.3-2014-023],[@b115-cmc-suppl.3-2014-023],[@b116-cmc-suppl.3-2014-023] Contribution of FABP5 to metabolic syndrome and cardiovascular diseases remains to be elucidated.

Ectopic FABP4 Expression
========================

There are accumulating evidences indicating FABP4 is expressed in several types of cells, in addition to adipocytes and macrophages, under both physiological and pathological conditions ([Fig. 4](#f4-cmc-suppl.3-2014-023){ref-type="fig"}). For example, expression of FABP4 was observed in endothelial cells of capillaries and small veins in the heart and kidney.[@b117-cmc-suppl.3-2014-023] As a physiological function, FABP4 in capillary endothelial cells of the heart and skeletal muscle interstitial capillaries is involved in transendothelial FA transport into FA-consuming organs.[@b118-cmc-suppl.3-2014-023] Treatment of endothelial cells with vascular endothelial growth factor-A (VEGF-A) via VEGF-receptor-2 (VEGFR2) or basic fibroblast growth factor (bFGF) induced FABP4 expression.[@b117-cmc-suppl.3-2014-023] FABP4 in endothelial cells has also been reported to promote angiogenesis.[@b119-cmc-suppl.3-2014-023]--[@b121-cmc-suppl.3-2014-023]

Interestingly, roles of FABP4 in vascular injury have been reported. FABP4 was markedly induced in regenerated endothelial cells after endothelial balloon denudation *in vivo*.[@b122-cmc-suppl.3-2014-023] Intermittent hypoxia also increased expression of FABP4 in human aortic endothelial cells.[@b123-cmc-suppl.3-2014-023] Conversely, anigiopoietin-1 inhibited FOXO1-mediated FABP4 expression in endothelial cells.[@b124-cmc-suppl.3-2014-023] FABP4 was expressed in the aortic endothelium of 12-week old, but not 8-week old, ApoE-deficient mice showing endothelial dysfunction.[@b125-cmc-suppl.3-2014-023] Chronic treatment with BMS309403, a small molecule FABP4 inhibitor, significantly improved endothelial dysfunction in ApoE-deficient mice.[@b125-cmc-suppl.3-2014-023] Notably, it has recently been shown the possible involvement of FABP4 and FABP5 in senescence of endothelial cells.[@b126-cmc-suppl.3-2014-023],[@b127-cmc-suppl.3-2014-023] These observations support the notion that ectopic expression of FABP4 under pathological condition, but not physiological FABP4 expression, in the endothelium contributes to the pathogenesis of atherosclerosis and vascular injury.

In normal kidneys, FABP4 is expressed in endothelial cells of the tubulointerstitial peritubular capillary and vein in both the cortex and medulla, but not in glomerular or arterial endothelial cells, under normal physiological condition.[@b117-cmc-suppl.3-2014-023] We recently demonstrated that ectopic expression of FABP4 in the glomerulus is associated with progression of proteinuria and renal dysfunction.[@b128-cmc-suppl.3-2014-023] Among FABPs, FABP1 (L-FABP) is expressed in proximal tubular epithelial cells in the kidney, and urinary FABP1 has been reported to reflect damage of proximal tubular epithelial cells.[@b129-cmc-suppl.3-2014-023],[@b130-cmc-suppl.3-2014-023] Our recent study[@b131-cmc-suppl.3-2014-023] suggests that urinary FABP4 is a novel biomarker reflecting glomerular damage and that determination of both FABP1 and FABP4 in urine enables better characterization of renal injury.

Evidences for the involvement of FABP4 in respiratory diseases have also been accumulating. FABP4 was detected in endothelial cells of peribronchial blood vessels and a subset of macrophages in lungs and bronchoalveolar samples from patients with bronchopulmonary dysplasia (BPD).[@b132-cmc-suppl.3-2014-023] Several studies using lung lavage cells suggested that expression of FABP4 is involved in pathogenesis of sarcoidosis.[@b133-cmc-suppl.3-2014-023] Furthermore, the Th2 cytokines IL-4 and IL-13, which are involved in the development of asthma, increased FABP4 expression in bronchial epithelial cells, and the Th1 cytokine interferon γ suppressed expression of FABP4.[@b38-cmc-suppl.3-2014-023] Interestingly, FABP4-deficient mice showed protection against asthma and airway inflammation through FABP action in stromal cells but not bone marrow-derived cells.[@b38-cmc-suppl.3-2014-023]

It has been reported that FABPs, including FABP4, are expressed in human placental trophoblasts and that FABP4 is a key regulator of trophoblastic lipid transport and accumulation during placental development.[@b134-cmc-suppl.3-2014-023]--[@b136-cmc-suppl.3-2014-023] FABP4 was detected in apoptotic granulosa cells in atretic antral follicles of the mouse ovary,[@b137-cmc-suppl.3-2014-023] suggesting a possible relevance to polycystic ovary syndrome (PCOS), which is known to frequently coexist with insulin resistance. Expression of *Fabp4* mRNA in isolated granulosa cells was higher in patients with PCOS than in controls.[@b138-cmc-suppl.3-2014-023] Association of FABP4 gene polymorphisms with the development of PCOS has also been reported.[@b139-cmc-suppl.3-2014-023]

Roles of FABP4 in modifications of tumor cell growth and apoptosis have been suggested by several studies. In ovarian cancer metastasis, FABP4 was detected in human ovarian cancer cells at the adipocyte--tumor cell interface, and FABP4 deficiency in mice substantially impaired metastatic tumor growth.[@b140-cmc-suppl.3-2014-023] FABP4 expression was also detected in lipoblasts of lipoblastoma and liposarcoma.[@b141-cmc-suppl.3-2014-023] Moreover, expression of FABP4 has been linked to glioblastoma[@b142-cmc-suppl.3-2014-023] and urothelial carcinomas.[@b143-cmc-suppl.3-2014-023] Additionally, treatment of mouse spleen and cultured T lymphocytes with dexamethasone induced FABP4 expression and its nuclear localization in association with apoptosis process.[@b144-cmc-suppl.3-2014-023]

FABP4 as a Therapeutic Target
=============================

The expression, regulation, and metabolic function of intracellular and extracellular human FABP4 have been reported to be similar to those of mouse FABP4.[@b10-cmc-suppl.3-2014-023],[@b25-cmc-suppl.3-2014-023],[@b36-cmc-suppl.3-2014-023],[@b72-cmc-suppl.3-2014-023] In fact, individuals with T-87C, a genetic variant of the human FABP4 gene within the promoter region, were protected from obesity-induced type 2 diabetes and exhibited diminished FABP4 expression in adipose tissue, lower triglyceride levels, and reduced cardiovascular disease risk.[@b105-cmc-suppl.3-2014-023] These findings provide a critical proof-of-principle that the biological functions of FABP4 are similar in mice and humans.

Since FABP4 acts at the interface of metabolic and inflammatory pathways and plays a significant role in the development of obesity, insulin resistance, type 2 diabetes, and atherosclerosis as described above, it is expected that agents capable of modifying FABP4 function would become a new class of therapeutic agents with multi-indications. To date, several series of FABP4 inhibitors have been synthesized.[@b6-cmc-suppl.3-2014-023],[@b145-cmc-suppl.3-2014-023]--[@b150-cmc-suppl.3-2014-023] We previously demonstrated the effect of BMS309403, a specific FABP4 inhibitor, on insulin resistance, diabetes mellitus, fatty liver disease, and atherosclerosis in experimental models,[@b151-cmc-suppl.3-2014-023] indicating that chemical inhibition of FABP4 could be a therapeutic strategy against several aspects of metabolic syndrome. BMS309403 is an orally active small molecule and interacts with the FA-binding pocket within the interior of FABP4 to inhibit binding of endogenous FAs ([Fig. 1](#f1-cmc-suppl.3-2014-023){ref-type="fig"}).[@b6-cmc-suppl.3-2014-023],[@b147-cmc-suppl.3-2014-023],[@b151-cmc-suppl.3-2014-023] In addition, a recent study showed that neutralization of secreted FABP4 by neutralizing antibodies reduced hepatic glucose production and corrected the diabetic phenotype of obese mice.[@b72-cmc-suppl.3-2014-023] Neutralizing or eliminating secreted FABP4 may also represent an effective therapeutic strategy against metabolic and cardiovascular diseases ([Fig. 3](#f3-cmc-suppl.3-2014-023){ref-type="fig"}). Further studies are obviously needed to investigate whether chemical or other types of inhibition and neutralization of FABP4 can be safely used in humans and to show the efficacy of agents for metabolic and cardiovascular diseases.

Concluding Remarks
==================

FABP4 is involved in the regulation of glucose and lipid metabolism in relation to inflammatory and metabolic processes in target cells, especially adipocytes and macrophages. Under normal physiologic conditions, FABP4-deficient mice have no compromised phenotype.[@b25-cmc-suppl.3-2014-023],[@b53-cmc-suppl.3-2014-023] However, FABP4-deficient mice on dietary or genetic obesity were protected from systemic pathologic stresses such as metaflammation, suggesting that the FABP4 gene would be one of the thrifty genes.[@b152-cmc-suppl.3-2014-023] FABPs have been evolutionarily preserved from invertebrates (lower eukaryotes) to vertebrates including humans,[@b12-cmc-suppl.3-2014-023] indicating a close link between inflammatory and metabolic responses by the conserved function of FABP. The presence of FABP4 in cells may have been beneficial for storing energy in adipose tissue or for acting as a strong immune response in macrophages against pathogens. In addition, secreted FABP4 in association with lipolysis during fasting may regulate hepatic glucose production as the thrifty phenotype to survive in famine. Under contemporary lifestyle with excessive caloric intake and decreased energy expenditure, the presence, induction, or enhanced secretion of FABP4 may be rather disadvantageous for regulating inflammatory or metabolic homeostasis. In recent metabolic disorders, as an evolutionary bottleneck in humans, inhibition or neutralization of FABP4 could be a promising novel class of therapeutics against several metabolic and cardiovascular diseases, and possibly other diseases such as asthma and cancer metastasis as well.
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![Association of FABP4 in adipocytes and macrophages with metabolic and cardiovascular diseases. FABP4 acts at the interface of metabolic and inflammatory pathways in adipocytes and macrophages and plays important roles in the development of insulin resistance, diabetes mellitus, and atherosclerosis. Chemical inhibition of FABP4 could be a therapeutic strategy against metabolic and cardiovascular diseases. BMS309403, one of the specific FABP4 inhibitors, is an orally active small molecule and interacts with the fatty acid-binding pocket within the interior of FABP4 to inhibit binding of endogenous fatty acid (FA). Intracellular FA-bound FABP4 (PDB code: 2hnx). Inhibitor-bound FABP4 (PDB code: 2nnq).](cmc-suppl.3-2014-023f1){#f1-cmc-suppl.3-2014-023}

![Secretion of FABP4 in association with lipolysis. FABP4 lacks an N-terminal secretory signal sequence, which is necessary for the classical ER--Golgi-dependent secretory pathway, but FABP4 can be secreted via the ER--Golgi-independent pathway. FABP4 is secreted from adipocytes in association with two distinct signal pathways of activation of lipolysis by phosphorylation of HSL, including β-adrenergic receptor-mediated AC-PKA and NPR-A-mediated GC-PKG pathways. FABP4 also interacts with HSL for regulation of its activity. FABP4 may be a carrier protein for transport of FAs generated by lipolysis from lipid droplets to extracellular and/or intracellular utilization.\
**Abbreviations:** AC, adenyl cyclase; AR, adrenergic receptor; ATGL, adipose triglyceride lipase; AQP7, aquaporin 7; DAG, diacylglyceride; ER, endoplasmic reticulum; FA, fatty acid; GC, guanylyl cyclase; HSL, hormone-sensitive lipase; MAG, monoacylgyceride; MGL, monoacylglycerol lipase; NPR-A, natriuretic peptide receptor-A; TAG, triacylglyceride; IRS-1, insulin receptor substrate 1; PDE-3B, phosphodiesterase 3B; PI3K, phosphatidylinositol-3-kinase; PKA, protein kinase A; PKB, protein kinase B; PKG, protein kinase G.](cmc-suppl.3-2014-023f2){#f2-cmc-suppl.3-2014-023}

![Possible action of circulating FABP4. FABP4 is secreted from adipocytes in association with lipolysis and may contribute to the development of insulin resistance, diabetes mellitus, atherosclerosis, hypertension, and cardiac dysfunction, leading to poor prognosis by cardiovascular death. Metabolic and cardiovascular disease-mediated activation of the sympathetic nerve system and/or induction of inflammatory cytokines may increase lipolysis in adiocytes, resulting in a vicious spiral of additional production of secreted FABP4. Inhibition or neutralization of secreted FABP4 may represent an effective therapeutic strategy against metabolic and cardiovascular diseases.](cmc-suppl.3-2014-023f3){#f3-cmc-suppl.3-2014-023}

![Potential association of FABP4 in several pathological conditions. FABP4 (A-FABP/aP2) is expressed not only in adipocytes and macrophages but also in several types of tissues and cells under physiological and pathophysiological conditions and may contribute to several aspects of metabolic and cardiovascular diseases as well as renal, respiratory, gynecological, and oncological diseases.](cmc-suppl.3-2014-023f4){#f4-cmc-suppl.3-2014-023}
